Literature DB >> 35530745

Relationship between coronary function testing and migraine: results from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction project.

Jessica Siak1, Chrisandra L Shufelt1, Galen Cook-Wiens2, Bruce Samuels1, John W Petersen3, R David Anderson3, Eileen M Handberg3, Carl J Pepine3, C Noel Bairey Merz1, Janet Wei1.   

Abstract

Aim: To determine the relationship between coronary vascular dysfunction and history of migraines in women with suspected ischemia and no obstructive coronary arteries (INOCA).
Methods: In the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction study, 402 women with suspected INOCA answered baseline angina questionnaires, including the Seattle Angina Questionnaire (SAQ). Coronary function testing (CFT) performed in a subgroup of 252 women evaluated for nonendothelial and endothelial-dependent coronary vascular function. Wilcoxon rank sum test, t-test, and linear regression models were performed.
Results: Of the 252 women who underwent CFT, 126 (50%) women reported migraine history. Compared to women who reported no migraines, women with migraines were younger and more were premenopausal. They had more angina at rest, with strong emotions, and hot/cold temperatures, as well as angina that wakes them from sleep (P < 0.05 for all). Women with migraines also scored worse on SAQ angina frequency and quality of life P < 0.01 for both). There was no difference in prevalence of coronary vascular dysfunction in the two groups. In addition, linear regression models demonstrated no significant age-adjusted differences in absolute CFT variables.
Conclusion: Among women with suspected INOCA, migraine history is prevalent and women with migraines have worse angina compared to those without migraines. Coronary vascular dysfunction diagnosed by CFT does not appear to relate to migraine history.

Entities:  

Keywords:  Women; angina; coronary microvascular dysfunction; migraines

Year:  2021        PMID: 35530745      PMCID: PMC9075042          DOI: 10.20517/2574-1209.2021.55

Source DB:  PubMed          Journal:  Vessel Plus        ISSN: 2574-1209


INTRODUCTION

Migraine headaches are associated with an increased risk of cardiovascular adverse outcomes, with accumulating evidence suggesting more elevated risk among women[. The Women’s Ischemia Syndrome Evaluation (WISE) found that, among women with signs and symptoms of ischemic heart disease, those with history of migraine headaches had an 83% excess major cardiovascular event risk at long-term follow-up, adjusted for traditional cardiovascular risk factors and coronary artery disease severity[. Endothelial function and vasomotor reactivity have been hypothesized to play a role in both the pathophysiology of migraines and the related cardiovascular risk[. Accordingly, we investigated the relationships between coronary vascular dysfunction and migraine history in a new cohort of women with signs and symptoms of ischemia and no obstructive coronary arteries (INOCA).

METHODS

In the WISE-Coronary Vascular Dysfunction (WISE-CVD) project, 437 women with suspected INOCA completed standardized medical history and symptom questionnaires, including the Seattle Angina Questionnaire. Typical angina was defined as meeting all three criteria: (1) substernal discomfort; (2) precipitated by physical exertion or emotional stress; and (3) relieved within 10 min by rest or nitroglycerin. Nontypical angina was defined as all others not meeting the criteria for typical angina. Of the 279 women who underwent invasive coronary function testing, information pertaining to migraine headache was available for 252 women. Invasive coronary function testing was performed with a Doppler wire in the left anterior descending artery as the preferred artery, as previously described[. Coronary flow reserve (CFR) was calculated as the ratio of the average peak velocity (APV) at hyperemia to the APV at rest, in response to intracoronary adenosine infusions (18 and 36 mcg); we previously showed that this velocity reserve correlated closely with volumetric flow, and thus it was used to represent CFR[. Reduced microvascular function was defined as CFR ≤ 2.5. Endothelial-dependent function and the presence of epicardial spasm were evaluated in response to intracoronary infusion of acetylcholine (10−4 mol/L) at 18.2 mcg/mL for 3 min, at an infusion rate of 0.8 mL/min. Coronary blood flow (CBF) response to acetylcholine was calculated from the Doppler-obtained APV and vessel diameter at baseline and post-acetylcholine, using the following equation: CBF = π (APV/2) (vessel diameter/2)2. Failure to increase the coronary blood flow (ΔCBF) > 50% was defined as abnormal microvascular endothelial-dependent function. A failure of coronary artery diameter to increase (or the presence of vasospasm) was considered abnormal macrovascular endothelial-dependent function. Abnormal nonendothelial-dependent macrovascular function was defined as coronary diameter response ≤ 20% increase to intracoronary nitroglycerin 200 mcg. Wilcoxon rank sum test, t-test, and linear regression models were performed to compare those with and without migraine history.

RESULTS

Table 1 compares the angina and coronary function testing results in the women stratified by migraine history. Migraine history was reported in 126 (50%) women. Compared to women without migraines, those with migraines were younger (52 ± 11 years vs. 56 ± 12 years, P = 0.006) and less frequently postmenopausal (60% vs. 76%, P = 0.01). There were no significant differences in body mass index or traditional cardiovascular risk factors comparing the two groups. While there was no difference in prevalence of typical vs. nontypical angina between the two groups, women with migraines had more frequent angina and poorer quality of life, which remained significant after adjusting for age. Women with migraines were also more likely to have angina with sexual activity, at rest, with strong emotions, with hot/cold temperatures, and waking them from sleep.
Table 1.

Angina questionnaire and coronary function testing results in women stratified by migraine history

Results (mean ± SD or %)No migraine history (n = 126)Migraine history (n = 126)P value
Seattle Angina Questionnaire
Physical limitation68 ± 2565 ± 240.29
Angina stability49 ± 2644 ± 290.14
Angina frequency68 ± 2558 ± 26 0.001
Treatment satisfaction73 ± 2468 ± 240.19
Quality of life54 ± 2445 ± 23 0.006
SAQ-7 score82 ± 2273 ± 21 0.002
Characteristics of angina
Typical angina43 (37%)55 (45%)0.23
Non typical angina73 (63%)68 (55%)
What brings on these sensations?
Whole body exertion, n = 23752 (44%)60 (50%)0.33
Sexual activity, n = 23113 (12%)30 (25%) 0.007
Strong emotions or stressful situations, n = 23662 (53%)78 (66%) 0.03
When it’s very hot or very cold, n = 23728 (24%)43 (36%) 0.03
Nothing at all (it happens at rest), n = 23667 (57%)86 (73%) 0.01
What usually relieves these sensations?
Stopping activity that brought it on, n = 23460 (52%)63 (53%)0.80
Rest, n = 23570 (60%)79 (66%)0.34
Nitroglycerin, n = 23537 (32%)48 (40%)0.18
Nothing seems to relieve it, n = 23424 (21%)20 (17%)0.50
Do these feelings ever
Wake you from sleep, n = 23447 (40%)81 (69%) < 0.0001
Coronary function measures
CFR to adenosine2.7 ± 0.72.70 ± 0.560.99
ΔCBF to acetylcholine56 ± 8575 ± 84 0.04
Coronary diameter response to acetylcholine−0.37 ± 15−0.01 ± 150.55
Coronary diameter response to nitroglycerin14 ± 1416 ± 140.41
Prevalence of coronary vascular dysfunction
Nonendothelial microvascular dysfunction (CFR < 2.5 to adenosine), n = 23647 (40%)41 (35%)0.50
Endothelial microvascular dysfunction (ΔCBF ≤ 50% to acetylcholine), n = 19054 (60%)48 (48%)0.11
Endothelial macrovascular dysfunction (diameter response ≤ 0% to acetylcholine), n = 22355 (50%)52 (46%)0.69
Nonendothelial macrovascular response (diameter response ≤ 20% to nitroglycerin), n = 22275 (67%)69 (63%)0.57
Any abnormal measure above, n = 18483 (94%)79 (82%) 0.01

Seattle Angina Questionnaire (0–100, lower value indicates worse angina); SAQ-7 (shortened version of the SAQ including the physical limitation, angina frequency, and quality of life domains). ΔCBF: Coronary blood flow change; CFR: coronary flow reserve; SAQ: Seattle Angina Questionnaire.

Compared to women without migraines, women with migraines had greater CBF response, suggesting better microvascular endothelial function, and they were less likely to have at least one abnormal coronary function measure. However, there was no difference in prevalence of coronary vascular dysfunction comparing the two groups, and linear regression models demonstrated no significant age-adjusted differences in the coronary function measures.

DISCUSSION

Among women with suspected INOCA, migraine history was prevalent in half of the cohort, and those with migraines were younger and had worse angina compared to women without migraines. However, coronary vascular dysfunction by invasive coronary function testing was not associated with migraine history when adjusted by age. To our knowledge, these findings are the first to assess nonendothelial and endothelial-dependent coronary vascular function in women with and without reported migraine history. The higher prevalence of angina in women with migraine history is consistent with a prior report from the Atherosclerosis Risk in Communities Study, which found that, among 12,409 men and women, those with a history of migraines and other headaches were more likely to have a history of angina than those without headaches[. While our angina data are consistent with the original WISE report of no difference in prevalence of typical or nontypical angina symptoms[, our detailed symptom questionnaires now highlight differences in angina triggers and other angina characteristics. We suspect this difference is likely related to the inclusion of women with both obstructive and nonobstructive coronary disease in the original WISE cohort, in which about a third had obstructive disease. This is in contrast to the WISE-CVD cohort, which included only women with no obstructive coronary arteries, allowing more specific analysis of angina suspected to be INOCA. In our investigation, coronary vascular dysfunction as diagnosed by invasive coronary function testing was not significantly different in women with vs. without migraine history. The difference in coronary microvascular endothelial function (ΔCBF) was no longer significant when adjusted for age. Compared to women without migraine history, women with migraine history had a higher prevalence of normal invasive coronary function testing (18% vs. 6%, P = 0.01), which suggests that there may be alternate mechanisms contributing to their chest pain, such as heightened cardiac nociception or autonomic dysfunction[. Prior studies have suggested autonomic imbalance in patients with migraines, particularly in those with aura[. Indeed, we found that women with migraines had a higher prevalence of angina triggered by emotional stress and temperature extremes, which can also be triggers for migraine attacks[. Invasive coronary function testing of this cohort did not include administration of high-dose acetylcholine (100 mcg) or 12-lead electrocardiographic monitoring in the assessment of epicardial and microvascular coronary spasm, thus limiting our ability to evaluate relationships between migraine history and vasospasm. A recent large study of patients with suspected INOCA undergoing invasive acetylcholine testing for coronary vasospasm found similar results with no significant difference in frequency of migraine in patients with epicardial vasospasm, microvascular vasospasm, and normal acetylcholine testing, although this study included both male and female patients, which may account for the lower frequency of migraines reported (11%)[. Since epicardial vasospasm has been found to be more prevalent in women than men with suspected INOCA[ and since women are three times more likely than men to have migraines[, further study of sex differences in vascular dysfunction and migraine may help understand the mechanisms related to increased cardiovascular risk in women with migraines. Limitations to this current analysis include absence of available vascular or hormonal biomarkers that may help provide further insight, since migraine history was more frequently reported in premenopausal women. Additionally, the left anterior descending artery was the preferred artery for coronary function testing, thus the presence of coronary vascular dysfunction in other arteries was not evaluated. Another limitation of our cohort study pertains to self-reported migraine diagnosis rather than determined using International Headache Society criteria. Data regarding intake of specific migraine medication were not available to assess any potential relationships among antimigraine medication use, angina characteristics, and coronary vascular function, as ergotamine derivatives and triptans have coronary vasoconstrictive properties[. In conclusion, our findings suggest that coronary vascular dysfunction may not be linked with migraine headaches to increase risk for cardiovascular events in women. Although our analysis did not demonstrate an association between migraine history and coronary vascular dysfunction, further larger, prospective studies that include higher dose acetylcholine-mediated vasospasm testing are needed to better understand the association between migraines and adverse cardiovascular outcomes in women.
  14 in total

1.  Migraines, angiographic coronary artery disease and cardiovascular outcomes in women.

Authors:  Bina Ahmed; C Noel Bairey Merz; Candace McClure; B Delia Johnson; Steve E Reis; Vera Bittner; Carl J Pepine; Barry L Sharaf; George Sopko; Sheryl F Kelsey; Leslee Shaw
Journal:  Am J Med       Date:  2006-08       Impact factor: 4.965

2.  Sex-Related Differences in Vasomotor Function in Patients With Angina and Unobstructed Coronary Arteries.

Authors:  Ahmed Aziz; Henrik Steen Hansen; Udo Sechtem; Eva Prescott; Peter Ong
Journal:  J Am Coll Cardiol       Date:  2017-11-07       Impact factor: 24.094

3.  Long-Term Follow-Up in Patients With Stable Angina and Unobstructed Coronary Arteries Undergoing Intracoronary Acetylcholine Testing.

Authors:  Andreas Seitz; Jenia Gardezy; Giancarlo Pirozzolo; Sabine Probst; Anastasios Athanasiadis; Stephan Hill; Heiko Mahrholdt; Raffi Bekeredjian; Udo Sechtem; Peter Ong
Journal:  JACC Cardiovasc Interv       Date:  2020-07-29       Impact factor: 11.195

Review 4.  Migraine: maladaptive brain responses to stress.

Authors:  Nasim Maleki; Lino Becerra; David Borsook
Journal:  Headache       Date:  2012-10       Impact factor: 5.887

5.  Design, methodology and baseline characteristics of the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD).

Authors:  Odayme Quesada; Ahmed AlBadri; Janet Wei; Chrisandra Shufelt; Puja K Mehta; Jenna Maughan; Nissi Suppogu; Haider Aldiwani; Galen Cook-Wiens; Michael D Nelson; Behzad Sharif; Eileen M Handberg; R David Anderson; John Petersen; Daniel S Berman; Louise E J Thomson; Carl J Pepine; C Noel Bairey Merz
Journal:  Am Heart J       Date:  2019-12-05       Impact factor: 4.749

6.  Coronary side-effect potential of current and prospective antimigraine drugs.

Authors:  A MaassenVanDenBrink; M Reekers; W A Bax; M D Ferrari; P R Saxena
Journal:  Circulation       Date:  1998-07-07       Impact factor: 29.690

Review 7.  Migraine and Autonomic Dysfunction: Which Is the Horse and Which Is the Jockey?

Authors:  Mitchell G Miglis
Journal:  Curr Pain Headache Rep       Date:  2018-02-23

8.  Migraine Headache and Long-Term Cardiovascular Outcomes: An Extended Follow-Up of the Women's Ischemia Syndrome Evaluation.

Authors:  Cecil A Rambarat; Islam Y Elgendy; B Delia Johnson; Steven E Reis; Diane V Thompson; Barry L Sharaf; Vera Bittner; George Sopko; C Noel Bairey Merz; Carl J Pepine; Bina Ahmed
Journal:  Am J Med       Date:  2017-01-19       Impact factor: 5.928

9.  The influence of weather on migraine - are migraine attacks predictable?

Authors:  Jan Hoffmann; Tonio Schirra; Hendra Lo; Lars Neeb; Uwe Reuter; Peter Martus
Journal:  Ann Clin Transl Neurol       Date:  2014-12-16       Impact factor: 4.511

Review 10.  Migraine Headache: An Under-Appreciated Risk Factor for Cardiovascular Disease in Women.

Authors:  Islam Y Elgendy; Stephen E Nadeau; C Noel Bairey Merz; Carl J Pepine
Journal:  J Am Heart Assoc       Date:  2019-11-11       Impact factor: 6.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.